title: [Helicobacter pylori-induced cost-benefit risk considerations].
authors.affiliation: Deutsche Klinik für Diagnostik, Fachbereich Gastroenterologie, Wiesbaden.
authors.forename: O
authors.initials: O
authors.lastname: Leiss
mesh_terms: D001729:Bismuth / Q000627:therapeutic use; D002169:Campylobacter Infections / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000191:economics*; D005260:Female; D005756:Gastritis / Q000188:drug therapy / Q000191:economics*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D012307:Risk Factors; D013276:Stomach Ulcer / Q000188:drug therapy / Q000191:economics*
chemical_list: D006635:Histamine H2 Antagonists; D001729:Bismuth
vernacular_title: Helicobacter-pylori-induzierte Kosten-Nutzen-Risiko-Uberlegungen.